proState Cancer Health Education to pRomote Early sreENing Uptake (SCREEN): A Pilot Randomised Control Trial
SCREEN
1 other identifier
interventional
74
0 countries
N/A
Brief Summary
Prostate cancer is an issue of significant public health concern. Yet in low- and middle-income countries like Nigeria, men are adversely affected due to factors including poor early prostate cancer screening uptake. Yet a gap remains in addressing this urgent problem. The proposed study seeks to pilot the feasibility and acceptability of a novel co-produced workshop intervention called "proState Cancer awareness education to pRomote Early screENing uptake (SCREEN) with men who are not or partially up to date with their screening. The SCREEN intervention is designed to raise awareness of prostate cancer, its symptoms, implications for late screening, the benefits of early screening, avenues for screening uptake, and also addressing anxiety related to screening uptake. The SCREEN intervention is low-intensity and lasts approximately two hours. The proposed study also aims to pilot and test the instrument to determine its effectiveness and cost-effectiveness, including the mechanism by which the intervention might work.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable anxiety
Started Sep 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 29, 2026
CompletedFirst Posted
Study publicly available on registry
September 2, 2026
CompletedStudy Start
First participant enrolled
September 15, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2027
September 2, 2026
August 1, 2026
1 year
August 29, 2026
August 29, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Service Satisfaction Scale
A five item scale that can be used to assess and measure satisfaction, acceptability and quality of the intervention. Higher score denote positive outcomes and acceptability. Lower score denotes poor satisfaction and acceptability.
At the end of intervention (day 2)
Secondary Outcomes (6)
Generalised Anxiety Disorder (GAD-7)
Baseline (day 1) and at the end of intervention (day 2)]
Oslo Social Support Scale (OSSS-3)
Baseline (day 1) and at the end of intervention (day 2)
European Quality of Life Scale EQ-5D-5L
Baseline (day 1) and at the end of intervention (day 2)
Knowledge of prostate cancer and screening scale
Baseline (day 1) and at the end of intervention (day 2)]
Beliefs around prostate cancer and screening intention scale
Baseline (day 1) and at the end of intervention (day 2)
- +1 more secondary outcomes
Study Arms (2)
proState Cancer awareness education to pRomote Early screENing uptake (SCREEN)
EXPERIMENTAL2 hour worksop session to foster awareness and encourage screening uptake
Control group
ACTIVE COMPARATORThe control group will receive intervention as usual. This may be in the form of existing prostate cancer screening information provided in hospitals, media and health centres.
Interventions
Existing information provided by health care provider, including media around prostate cancer.
The SCREEN intervention is designed to raise awareness of prostate cancer, its symptoms, implications for late screening, the benefits of early screening, avenues for screening uptake, and also addressing anxiety related to screening uptake. The SCREEN intervention is low-intensity and lasts approximately two hours.
Eligibility Criteria
You may qualify if:
- Men aged between age 18 years and 79 who are not or partially up to date with prostate cancer
- Able to provide full consent for their participation.
- Able to speak the English Language. Able to take part in the intervention and are available for the intervention assessment at baseline and end of intervention.
You may not qualify if:
- Less than 18 years
- Unable to consent.
- Currently undergoing severe mental health treatment.
- Unable to speak the English language
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Teesside Universitylead
- Jos University Teaching Hospitalcollaborator
- University of Manchestercollaborator
Related Publications (3)
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20.
PMID: 31068988BACKGROUNDDozie INS, Chukwuocha UM, Innocent DC, Dozie UW, Chukwuemeka PS. A systematic review and meta-analysis of the prevalence and risk factors of prostate cancer in Nigeria. BMC Cancer. 2025 Nov 26;25(1):1932. doi: 10.1186/s12885-025-15358-4.
PMID: 41299322BACKGROUNDAbdus-Salam AA, Jimoh MA, Folasire AM, Ntekim AI, Ojo OT, Ehiedu CG, Yusuf SA, Takure AO, Akinlade BI, Idowu OK, Oladeji AA, Sarimiye FO, Adenipekun AA. Sociodemographic and clinicopathologic characteristics of patients treated with high dose rate prostate brachytherapy in Nigeria. Ecancermedicalscience. 2024 Aug 14;18:1740. doi: 10.3332/ecancer.2024.1740. eCollection 2024.
PMID: 39421165BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior Lecturer
Study Record Dates
First Submitted
August 29, 2026
First Posted
September 2, 2026
Study Start
September 15, 2026
Primary Completion (Estimated)
September 30, 2027
Study Completion (Estimated)
September 30, 2027
Last Updated
September 2, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share
Data supporting this study cannot be made available due to the sensitive nature and ethical reasons on confidentiality.